KUALA LUMPUR, Aug 3 (Bernama) -- Graminex® LLC has announced that the US Patent Office has rejected Serelys' patents for use of its pollen extracts in treating women's premenstrual syndrome (PMS) and menopausal symptoms.
In a statement, the company said that in parallel re-examination proceedings against US Patents 6,569,471 and 6,669,967, the US Patent Office recently rejected all claims of both patents.
Based on overwhelming evidence submitted, the Office found the claimed solvent-extracted GC FEM and PI 82 pollen extracts, for use in treating PMS and menopausal symptoms in women, to be unpatentable.
Graminex® LLC is the leading producer of natural and solvent-free Graminex® Flower Pollen Extract.
The company markets clinically supported Flower Pollen Extracts, focusing on prostate care, urinary care, menopausal support, and skin care.
Partnered with its distributors, retailers and manufacturers, Graminex® products are made in the USA and sold in more than 44 countries on six continents.
More details at https://www.graminex.com
--BERNAMA
No comments:
Post a Comment